Skip to main content

Pemphigoid, Bullous

Sujitha Yadlapati, MD and Faraz Yousefian, DO Reviewed 06/2022
 


BASICS

DESCRIPTION

  • Bullous pemphigoid (BP) is a chronic, acquired autoimmune subepidermal blistering skin disorder caused by linear deposition of autoantibodies against the epithelial basal membrane zo...

DIAGNOSIS

HISTORY

  • BP occurs sporadically without any obvious trigger factor.

  • Prodromal nonbullous phase: mild to severe pruritus, associated with excoriated, eczematous, and often urticarial plaques

  • Muco...

TREATMENT

GENERAL MEASURES

  • Discontinue trigger factors.

  • Secondary infection should be treated aggressively with systemic antibiotics.

  • Depending on the extent of the disease, consultation with dentistry, ...

ONGOING CARE

FOLLOW-UP RECOMMENDATIONS

Patient Monitoring

  • Taper medication when disease is stable and control side effects.

  • Perform periodic skin examination for new lesions.

  • Frequent bacterial cultures o...

REFERENCES

1
Patsatsi A, Kyriakou A, Werth VP. Bullous pemphigoid in adolescence. Pediatr Dermatol. 2019;36(2):184–188. doi: 10.1111/pde.13717.
2
Williams  HC, Wojnarowska  F, Kirt...

ADDITIONAL READING

  • Feliciani C, Joly P, Jonkman MF, et al. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatolo...

CODES

ICD10

L12.0 Bullous pemphigoid 

SNOMED

  • 77090002 Bullous pemphigoid (disorder)

  • 402440008 oral mucous membrane involvement by bullous pemphigoid (disorder)

  • 403629000 drug-induced bullous pemphigoid (di...

CLINICAL PEARLS

  • Tense bullae differentiate the lesions of bullous pemphigoid from the flaccid bullae of pemphigus vulgaris.

  • Low doses of potent topical steroid have been shown to be just as effective a...

Subscribe to Access Full Content

Sign Up for a 10-Day Free Trial

Sign up for a 10-day FREE Trial now and receive full access to all content.

 
×